BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference

BlossomHill Therapeutics (Nasdaq: BLSM) will participate in Guggenheim’s 3rd Annual Healthcare Innovations Conference on November 10, 2026, in Boston.

Rhea-AI Summary

BlossomHill Therapeutics (Nasdaq: BLSM) will participate in Guggenheim’s 3rd Annual Healthcare Innovations Conference on November 10, 2026, in Boston. Management’s fireside chat is scheduled for 3:00 pm Eastern Time at the Intercontinental Boston, alongside one-on-one investor meetings. An audio webcast will be accessible through the company’s investor website, with an archived replay available for 90 days.

Argus Nov 3 session 13 alerts

-0.08% close to close 1.1x rel. volume Open Argus

Details

News Market Reaction – BLSM

-13.5% Trough in 2 hr 3 min

$413.20M Mkt Cap at Peak Alert

On Nov 3, the day this news came out, BLSM closed 0.08% below the previous close. Argus tracked a trough of -13.5% from its starting point during tracking. Our momentum scanner recorded 13 alerts in the available session data.

Data tracked by StockTitan Argus for the Nov 3 session.

Key Terms

fast track designation, nsclc

2 terms

fast track designation regulatory

"received Fast Track designation for the C797S resistance population"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

nsclc medical

"EGFR-mutant non-small cell lung cancer (NSCLC)"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced its participation in Guggenheim’s 3^rd Annual Healthcare Innovations Conference being held at the Intercontinental Boston. Management will participate in a fireside chat on Tuesday, November 10, 2026, at 3:00 pm Eastern Time and will also participate in one-on-one investor meetings.

An audio webcast of the fireside chat can be accessed on the Events & Presentations page of the Investors section of BlossomHill’s website. An archived replay will be available for 90 days.

About BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical program is BH-30643, an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR^TM inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company’s pipeline also includes BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch-II inhibitor for potential future development in diverse KRAS-mutant tumors.

BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit www.bhtherapeutics.com and follow us on LinkedIn and X.

Company Contact:
Michael Moore, BlossomHill Therapeutics
michael.moore@bhtherapeutics.com

Media:
Ashlea Kosikowski, 1AB
ashlea@1abmedia.com